-
Spatial 3D genome organization reveals intratumor heterogeneity in primary glioblastoma samples. Sci Adv. 2025 Mar 14; 11(11):eadn2830.
Wang Q, Wang J, Mathur R, Youngblood MW, Jin Q, Hou Y, Stasiak LA, Luan Y, Zhao H, Hilz S, Hong C, Chang SM, Lupo JM, Phillips JJ, Costello JF, Yue F. PMID: 40073147; PMCID: PMC11900876.
View in:
PubMed Mentions: Fields:
Translation:
HumansCells
-
Overcoming heterogeneity with 3D whole-tumour sampling. Nat Rev Cancer. 2024 Dec; 24(12):825.
Mathur R. PMID: 39251837.
View in:
PubMed Mentions: Fields:
-
IMMU-59. AN IMMUNOSUPPRESSIVE PROGRAM ENCOMPASSING MULTIPLE IMMUNE CELL TYPES IN GBM TYPIFIED BY NOVEL MARKER LRRC25 ASSOCIATED WITH TYROBP SIGNALING. Neuro-Oncology. 2024 Nov 11; 26(Supplement_8):viii165-viii166.
Zamler ZD, Mathur MR, Chan CG, Schupp SP, Shai SA, Okada OH, Oldham OM, Costello CJ. .
View in:
Publisher Site Mentions:
-
Whole tumor analysis reveals early origin of the TERT promoter mutation and intercellular heterogeneity in TERT expression. Neuro Oncol. 2024 04 05; 26(4):640-652.
Appin CL, Hong C, Suwala AK, Hilz S, Mathur R, Solomon DA, Smirnov IV, Stevers NO, Shai A, Wang A, Berger MS, Chang SM, Phillips JJ, Costello JF. PMID: 38141254; PMCID: PMC10995505.
View in:
PubMed Mentions:
4 Fields:
Translation:
Humans
-
Abstract 5676: Spatial 3D genome organization reveals intratumor heterogeneity in primary glioblastoma samples. Cancer Research. 2024 Mar 22; 84(6_Supplement):5676-5676.
Wang WQ, Wang WJ, Mathur MR, Youngblood YM, Jin JQ, Hou HY, Stasiak SL, Luan LY, Costello CJ, Yue YF. .
View in:
Publisher Site Mentions:
-
Glioblastoma evolution and heterogeneity from a 3D whole-tumor perspective. Cell. 2024 01 18; 187(2):446-463.e16.
Mathur R, Wang Q, Schupp PG, Nikolic A, Hilz S, Hong C, Grishanina NR, Kwok D, Stevers NO, Jin Q, Youngblood MW, Stasiak LA, Hou Y, Wang J, Yamaguchi TN, Lafontaine M, Shai A, Smirnov IV, Solomon DA, Chang SM, Hervey-Jumper SL, Berger MS, Lupo JM, Okada H, Phillips JJ, Boutros PC, Gallo M, Oldham MC, Yue F, Costello JF. PMID: 38242087; PMCID: PMC10832360.
View in:
PubMed Mentions:
48 Fields:
Translation:
Humans
-
View in:
PubMed Mentions:
9 Fields:
Translation:
HumansCells
-
Abstract 3621: 3D spatial sampling and integrated omics reveal sources and patterning of intratumoral heterogeneity in glioblastoma. Cancer Research. 2022 Jun 15; 82(12_Supplement):3621-3621.
Mathur MR, Wang WQ, Schupp SP, Nikolic NA, Yamaguchi YT, Hilz HS, Hong HC, Smirnov SI, LaFontaine LM, Phillips PJ, Chang CS, Li LY, Lupo LJ, Boutros BP, Gallo GM, Oldham OM, Yue YF, Costello CJ. .
View in:
Publisher Site Mentions:
-
Abstract 3797: 3D whole tumor analysis of the TERT promoter mutation in gliomas. Cancer Research. 2022 Jun 15; 82(12_Supplement):3797-3797.
Appin AC, Suwala SA, Hilz HS, Mathur MR, Smirnov SI, Hong HC, Stevers SN, Shai SA, Wang WA, Berger BM, Chang CS, Phillips PJ, Costello CJ. .
View in:
Publisher Site Mentions:
-
PATH-28. RE-DEFINING CLONALITY OF THE TERT PROMOTER MUTATION WITH DEEP SEQUENCING AND MAXIMAL SAMPLING OF NEWLY DIAGNOSED AND RECURRENT GBM AND OLIGODENDROGLIOMA. Neuro-Oncology. 2021 Nov 12; 23(Supplement_6):vi121-vi121.
Appin AC, Suwala SA, Hilz HS, Mathur MR, Smirnov SI, Hong HC, Stevers SN, Shai SA, Berger BM, Chang CS, Phillips PJ, Costello CJ. .
View in:
Publisher Site Mentions:
-
Epigenomic contributions to tumor cell heterogeneity and plasticity. Nat Genet. 2021 10; 53(10):1403-1404.
Mathur R, Costello JF. PMID: 34608295.
View in:
PubMed Mentions: Fields:
-
ECOA-5. Integrative 3D spatial characterization of genomic and epigenomic intratumoral heterogeneity in glioblastoma. Neuro-Oncology Advances. 2021 Jul 5; 3(Supplement_2):ii2-ii2.
Mathur MR, Wang WQ, Schupp SP, Hilz HS, Hong HC, Smirnov SI, Lafontaine LM, Nair ND, Iyyanaki IS, Phillips PJ, Chang CS, Li LY, Lupo LJ, Oldham OM, Yue YF, Costello CJ. .
View in:
Publisher Site Mentions:
-
MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrence. Neuro Oncol. 2020 11 26; 22(11):1580-1590.
Mathur R, Zhang Y, Grimmer MR, Hong C, Zhang M, Bollam S, Petrecca K, Clarke J, Berger MS, Phillips JJ, Oberheim-Bush NA, Molinaro AM, Chang SM, Costello JF. PMID: 32166314; PMCID: PMC8444710.
View in:
PubMed Mentions:
47 Fields:
Translation:
HumansCells
-
EPCO-31. EPIGENOMIC INTRATUMORAL HETEROGENEITY OF GLIOBLASTOMA IN THREE-DIMENSIONAL SPACE. Neuro-Oncology. 2020 Nov 9; 22(Supplement_2):ii76-ii76.
Mathur MR, Iyyanki IS, Hilz HS, Hong HC, Phillips PJ, Chang CS, Yue YF, Costello CJ. .
View in:
Publisher Site Mentions:
-
GENE-35. MGMT PROMOTER METHYLATION IN NEWLY DIAGNOSED LGG AS A POTENTIAL BIOMARKER FOR TMZ-ASSOCIATED HYPERMUTATION AT RECURRENCE. Neuro-Oncology. 2019 Nov 11; 21(Supplement_6):vi105-vi105.
Mathur MR, Zhang ZY, Grimmer GM, Hong HC, Berger BM, Molinaro MA, Ann Oberheim-Bush AN, Chang CS, Costello CJ. .
View in:
Publisher Site Mentions:
-
ARID1A loss in cancer: Towards a mechanistic understanding. Pharmacol Ther. 2018 10; 190:15-23.
Mathur R. PMID: 29730444.
View in:
PubMed Mentions:
66 Fields:
Translation:
HumansAnimals
-
SWI/SNF (BAF) Complexes: Guardians of the Epigenome. Annual Review of Cancer Biology. 2018 Mar 4; 2(1):1-15.
Mathur MR, Roberts RC. .
View in:
Publisher Site Mentions:
-
SWI/SNF (BAF) Complexes: Guardians of the Epigenome. Annual Review of Cancer Biology. 2017; 2:413-427.
Radhika Mathur, Charles W. M. Roberts. View Publication.
-
Abstract LB-286: ARID1A loss impairs enhancer-mediated gene regulation and drives colon cancer in mice. Molecular and Cellular Biology, Genetics. 2017 Jul 1; lb-286-lb-286.
Mathur MR, Alver AB, Roman RA, Wilson WB, Wang WX, Agoston AA, Park PP, Shivdasani SR, Roberts RC. .
View in:
Publisher Site Mentions:
-
ARID1A loss impairs enhancer-mediated gene regulation and drives colon cancer in mice. Nat Genet. 2017 Feb; 49(2):296-302.
Mathur R, Alver BH, San Roman AK, Wilson BG, Wang X, Agoston AT, Park PJ, Shivdasani RA, Roberts CW. PMID: 27941798; PMCID: PMC5285448.
View in:
PubMed Mentions:
179 Fields:
Translation:
HumansAnimalsCells
-
Disruptive ARID1A Mutations in Follicular Lymphoma Impair DNA Repair Efficiency and Are Associated with Favorable Outcome in Patients Receiving First-Line Immunochemotherapy. Blood. 2015 Dec 3; 126(23):571.
Bararia BD, Heide HM, Welner WR, Romashova RT, Pastore PA, Mathur MR, Gascoyne GR, Kridel KR, Willson WB, Roberts RC, Hiddemann HW, Weinstock WD, Weigert WO. .
View in:
Publisher Site Mentions:
-
Disruptive ARID1A Mutations in Follicular Lymphoma Impair DNA Repair Efficiency and Are Associated with Favorable Outcome in Patients Receiving First-Line Immunochemotherapy. Blood. 2015 Dec 3; 126(23):571.
Bararia BD, Heide HM, Welner WR, Romashova RT, Pastore PA, Mathur MR, Gascoyne GR, Kridel KR, Willson WB, Roberts RC, Hiddemann HW, Weinstock WD, Weigert WO. .
View in:
Publisher Site Mentions: